Monthly Prescribing Reference

Brixadi Now Available for Weekly or Monthly Administration to Treat Opioid Use Disorder

Credit: Braeburn. Brixadi (weekly) and Brixadi (monthly) are different formulations. Brixadi ® (buprenorphine) extended-release subcutaneous injection is now available for the treatment of moderate to ...
Monthly Prescribing Reference

Brixadi Gets Tentative FDA Approval for Opioid Use Disorder

Braeburn announced that the Food and Drug Administration (FDA) has tentatively approved Brixadi (buprenorphine) extended-release weekly and monthly injections for the treatment of moderate to severe ...
ksn.com

BRIXADI® (buprenorphine) Extended-Release Injection for Subcutaneous Use (CIII) is Now Available in the U.S. for the Treatment of Moderate to Severe Opioid Use Disorder

BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. PLYMOUTH ...
Daily Local News

FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADITM (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder

PLYMOUTH MEETING, Pa., June 26, 2021 /PRNewswire/ — Braeburn announces that the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release weekly and monthly injection for subcutaneous ...
ksn.com

Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder

BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses. Patients currently on a transmucosal buprenorphine-containing product can be switched to an ...